Literature DB >> 10656996

Overlap of IGF- and heparin-binding sites in rat IGF-binding protein-5.

H Song1, J Beattie, I W Campbell, G J Allan.   

Abstract

Using site-directed mutagenesis, we have undertaken a study of a potential IGF-binding site in the C-terminal domain of rat IGFBP-5, lying close to or within a previously described heparin-binding domain (residues 201-218) in this protein. After analysis of binding activity using three different methods - ligand blotting, solution phase equilibrium binding and biosensor measurement of real-time on- and off-rates - we report that the mutation of two highly conserved residues within this region (glycine 203 and glutamine 209) reduces the affinity of the binding protein for both IGF-I and IGF-II, while having no effect on heparin binding. In addition, we confirm that mutation of basic residues within the heparin-binding domain (R201L, K202E, K206Q and R214A) results in a protein that has attenuated heparin binding but shows only a small reduction in affinity for IGF-I and -II. Previous findings have described the reduction in affinity of IGFBP-5 for IGFs that occurs after complexation of the binding protein with heparin or other components of the extracellular matrix (ECM) and have postulated that such an interaction may result in conformational changes in protein structure, affecting subsequent IGF interaction. Our data suggesting potential overlap of heparin- and IGF-binding domains argue for a more direct effect of ECM modulation of the affinity of IGFBP-5 for ligand by partial occlusion of the IGF-binding site after interaction with ECM.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10656996     DOI: 10.1677/jme.0.0240043

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  8 in total

Review 1.  Molecular interactions in the insulin-like growth factor (IGF) axis: a surface plasmon resonance (SPR) based biosensor study.

Authors:  James Beattie; Kirsten Phillips; John H Shand; Malgorzata Szymanowska; David J Flint; Gordon J Allan
Journal:  Mol Cell Biochem       Date:  2007-09-25       Impact factor: 3.396

Review 2.  Proteoglycans: pericellular and cell surface multireceptors that integrate external stimuli in the mammary gland.

Authors:  M Delehedde; M Lyon; N Sergeant; H Rahmoune; D G Fernig
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.673

Review 3.  Insulin-like growth factor binding protein-5 in osteogenesis: facilitator or inhibitor?

Authors:  Aditi Mukherjee; Peter Rotwein
Journal:  Growth Horm IGF Res       Date:  2007-02-21       Impact factor: 2.372

4.  Insulin-like growth factor-binding protein-5 inhibits osteoblast differentiation and skeletal growth by blocking insulin-like growth factor actions.

Authors:  Aditi Mukherjee; Peter Rotwein
Journal:  Mol Endocrinol       Date:  2008-02-21

Review 5.  Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis.

Authors:  James Beattie; Gordon J Allan; Jennifer D Lochrie; David J Flint
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

6.  Interstitial tissue-specific gene expression in mouse testis by intra-tunica albuguineal injection of recombinant baculovirus.

Authors:  Hyun Jung Park; Won Young Lee; Jin Hoi Kim; Jae Hwan Kim; Hun Jong Jung; Nam Hyung Kim; Bo Kyung Kim; Hyuk Song
Journal:  Asian J Androl       Date:  2009-01-26       Impact factor: 3.285

7.  Insulin-like growth factor binding proteins: a structural perspective.

Authors:  Briony E Forbes; Peter McCarthy; Raymond S Norton
Journal:  Front Endocrinol (Lausanne)       Date:  2012-03-02       Impact factor: 5.555

Review 8.  Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer.

Authors:  Mustafa Akkiprik; Yumei Feng; Huamin Wang; Kexin Chen; Limei Hu; Aysegul Sahin; Savitri Krishnamurthy; Ayse Ozer; Xishan Hao; Wei Zhang
Journal:  Breast Cancer Res       Date:  2008-08-11       Impact factor: 6.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.